Yahoo · Feb 27, 2026
Moderna’s Covid-Flu Vaccine Recommended for Approval in EU
The recommendation from regulators paves the way for the shot’s approval in the European Union at a time the company is facing scrutiny in the U.S.
NASDAQ · MRNA
Moderna, Inc.
Healthcare · Biotechnology
$222.76
Up+$8.60 (+4.01%)
Updated Oct 30, 2026, 6:41 AM
SID Score
7.1/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 11.57B
- P/E ratio
- -3.71
- Dividend yield
- 0.00%
- 52-week range
- $32.28 – $254.48
- Volume
- 10.83M
- Avg. volume
- 11.3M
Price performance · MRNA
MRNA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
MRNA closed at $222.76 after 21 trading sessions, up 17.90% for the selected period.
- Last close
- $222.76
- Period change
- +17.90%
- Period low
- $187.46
- Period high
- $245.81
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $216.43 | $225.00 | $215.35 | $222.76 | 10.83M |
| Oct 28, 2026 | $204.00 | $218.16 | $202.62 | $214.165 | 12.04M |
| Oct 27, 2026 | $192.23 | $208.87 | $179.53 | $207.97 | 17.64M |
| Oct 26, 2026 | $186.904 | $203.82 | $181.65 | $198.85 | 17.11M |
| Oct 23, 2026 | $196.69 | $206.97 | $183.00 | $200.10 | 21.57M |
| Oct 22, 2026 | $240.125 | $241.2642 | $180.80 | $202.63 | 49.95M |
| Oct 21, 2026 | $242.20 | $254.48 | $239.5501 | $245.81 | 16.01M |
| Oct 20, 2026 | $226.03 | $243.98 | $216.6512 | $242.08 | 16.86M |
| Oct 19, 2026 | $217.27 | $236.7699 | $216.00 | $226.89 | 18.79M |
| Oct 16, 2026 | $235.00 | $237.96 | $208.92 | $218.01 | 21.4M |
| Oct 15, 2026 | $225.48 | $242.29 | $217.0221 | $236.50 | 17.31M |
| Oct 14, 2026 | $217.49 | $227.09 | $211.24 | $226.30 | 16.63M |
| Oct 13, 2026 | $207.63 | $218.48 | $204.70 | $216.25 | 13.39M |
| Oct 12, 2026 | $224.50 | $227.46 | $210.91 | $213.74 | 12.87M |
| Oct 9, 2026 | $199.00 | $225.00 | $197.17 | $225.00 | 28.95M |
| Oct 8, 2026 | $196.42 | $199.92 | $192.71 | $197.00 | 37.4M |
| Oct 7, 2026 | $183.645 | $197.69 | $182.50 | $196.48 | 14.64M |
| Oct 6, 2026 | $202.09 | $212.22 | $186.64 | $187.46 | 18.79M |
| Oct 5, 2026 | $191.41 | $205.77 | $185.90 | $203.21 | 19.31M |
| Oct 2, 2026 | $190.26 | $193.72 | $183.28 | $190.01 | 10.29M |
| Oct 1, 2026 | $186.61 | $201.00 | $186.012 | $188.94 | 15.44M |
Latest MRNA news
The latest Smart Investors Daily articles mentioning MRNA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MRNA research
Overview
Company profile and research snapshot.
Company profile
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $29.64
- Implied upside
- —
- Analysts
- 29
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | William Blair | Market Perform | — |
| Oct 26, 2026 | Piper Sandler | Overweight | — |
| Oct 21, 2026 | TD Cowen | Hold | — |
| Oct 15, 2026 | Goldman Sachs | Neutral | — |
| Oct 7, 2026 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 27, 2026
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive CHMP opinion mCOMBRIAX will be made available in ...
Yahoo · Feb 27, 2026
Moderna’s combination flu, COVID shot wins over European drug regulators
In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for Moderna’s vaccine in the U.S.
Benzinga · Feb 27, 2026
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopts A Positive Opinion Recommending Approval Of Moderna's mCOMBRIAX (mRNA-1083), A Combination Vaccine For Influenza And Covid-19 For Individuals 50 Years Of Age And Older
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
